Enhancing Exercise Performance with Natural Products: A Comprehensive Review.

Atopic dermatitis is a long-term skin condition linked to immune-system activity and itching. This real-world study followed 80 adults with moderate-to-severe disease treated with lebrikizumab, including patients who switched directly from another systemic treatment. After six months, skin symptoms improved substantially: average severity score (Eczema Area and Severity Index, EASI) fell from 14.8 to 3.0, while itching and quality-of-life scores also decreased. By month six, 70% achieved at least 75% improvement in skin symptoms, and 50% achieved at least 90% improvement. Side effects occurred in 26.6% of the cases, most commonly eye problems. Overall, results matched clinical trials, supporting lebrikizumab’s effectiveness in routine care for adults with difficult-to-treat disease. Atopic dermatitis (AD) is a chronic, inflammatory skin disease characterized by intense itch and chronic or recurrent eczematous lesions. AD poses a remarkable burden on both patients and healthcare systems and often leads to reduction in quality of life and productivity (–). Its pathobiology is complex, but type 2 inflammation and in particular interleukin-13 (IL-13) and interleukin-4 (IL-4) are considered key drivers (, ). In recent years, the approval of innovative, targeted systemic therapies has greatly expanded the available therapeutic options (–). However, data from registries and health insurance records indicate that a considerable proportion of patients continue to suffer from suboptimal disease control and impaired quality of life, highlighting persistent gaps in care and the need for further innovation and more individualized therapeutic approaches (). Lebrikizumab, a high-affinity monoclonal antibody targeting interleukin-13, represents one of the most recent biologic options for the systemic treatment of moderate-to-severe AD. Randomized controlled trials (RCTs) and extension studies, together with several network meta-analyses (, ), demonstrated robust efficacy. With mean EASI reductions of up to 65% and EASI-75 response rates of approximately 60% as well as clinically relevant itch improvement in around 40% of patients at week 16 on monotherapy (), responses increase with concomitant TCS and longer-term therapy (, ). As experience from daily practice with lebrikizumab continues to grow, its precise role within the expanding therapeutic landscape for AD will continue to be defined. Here, we set out to investigate the treatment pattern, clinical effectiveness and safety of lebrikizumab under routine care conditions. TREATgermany is a registry for patients with moderate-to-severe AD receiving or eligible for systemic treatment. Details on the study design were published previously (). Currently >2,500 adult patients are followed-up prospectively. The medical faculty of the Technical University Dresden, Germany has granted approval for the registry (registration number EK 118032016). Moreover, all ethics committees at the participating sites have given their approval. The registry has been registered at clinicaltrials.gov () and in the ENCePP Resource Database.